Aurobindo Pharma is reportedly planning to ramp up its generic business in the western European markets. While, the company has acquired about 1,250 dossiers as part of its strategy to expand in the region, it is likely to launch some more new products in the current financial year.
In addition, there were about 100 products already exported from the manufacturing units in India. The company would leverage on its large scale manufacturing capabilities in India apart from the existing European infrastructure.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
